Hyderabad, Jan 23 (UNI) Suven Life Sciences Ltd today announced that the US Patent office has granted Product Patent US 7,317,035 to Suven, the company's second product patent granted in US.
The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by Suven and being developed as therapeutic agents.
According to the invention '035 patent disclosure, the compounds are useful in the treatment of neuro-degenerative disorders like Alzheimer's, Parkinsons, Schizophrenia and Huntington's.
Suven has so far filed 29 product patent applications through PCT, covering more than 145 countries, out of which five product patents had been granted in various countries. Several other patent applications from Suven Discovery Research are in the pipeline. They have completed the administrative and technical diligence from the patent offices from major countries and would be granted shortly.
Suven has filed its first Investigational New Drug (IND) application with DCGI to conduct the clinical Phase-I study on their developmental candidate SUVN-502 and several candidates are in discovery pipeline undergoing GLP pre-clinical studies.
UNI VA VV AK HT1704